Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Boosts HCV Portfolio With First-in-Class Debiopharm Compound

This article was originally published in The Pink Sheet Daily

Executive Summary

Hepatitis C sector heats up as Novartis gains rights to Debiopharm's leading cyclophilin inhibitor

You may also be interested in...



Novartis’ Hepatitis C Drug Alisporivir Returns To Clinical Testing Minus Interferon

Phase II trial of alisporivir plus ribavirin began after FDA modified its partial clinical hold; previous regimen included peg-interferon.

Novartis And HGS Close The Door On Zalbin

Development of hepatitis C drug concluded after FDA "complete response" letter and disappointing monthly dosing data.

Novartis And HGS Close The Door On Zalbin

Development of hepatitis C drug concluded after FDA "complete response" letter and disappointing monthly dosing data.

Related Content

Topics

UsernamePublicRestriction

Register

PS070314

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel